Refine by
Preclinical Study Technology
17 companies found
Technologybased inVerona, ITALY
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding ...
In Silico: Identifying small molecules able to revolutionize drug discovery. The PPI-FIT technology allows the exploration of unique pharmacological targets represented by protein folding intermediates. This places Sibylla Biotech in the exclusive ...
Technologybased inSouth San Francisco, CALIFORNIA (USA)
Neurona Therapeutics is driven by rigorous scientific discovery and focused on developing breakthrough treatments for neurological disorders. Neurona Therapeutics is a privately-held, clinical-stage biotherapeutics company focused on discovering and ...
Neurona’s lead product candidate, NRTX-1001, comprises human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001’s first indication is for the treatment of drug-resistant focal epilepsy, which is a ...
Technologybased inParis, FRANCE
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and ...
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients ...
Technologybased inNes-Ziona, ISRAEL
Kadimastem is a bio-pharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. ...
We Have Reached Successful Pre-clinical results of our cell Therapy Treatment for Insulin-Dependent Diabetes. Diabetes mellitus is a chronic disorder characterized by high blood glucose levels and glucose intolerance, due to insulin deficiency, ...
Technologybased inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by ...
Technologybased inRye Brook, NEW YORK (USA)
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is ...
Technologybased inLabège, FRANCE
Vaiomer microbiome studies and expert service supports your discoveries and innovations when identifying predictors and mechanisms associated with the development of chronic diseases. Vaiomer challenges the frontiers of microbiome research by ...
Animal models are essential in understanding the role of microbiomes in health and diseases whether the endpoint is to improve human or animal health. In basic research and preclinical studies, animal models such as ...
Technologybased inMiami, FLORIDA (USA)
We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B, which is derived from culture-expanded medicinal signaling cells (MSCs) ...
We have an ongoing Phase 1 sub-study exploring whether Lomecel-B can improve the Metabolic Syndrome, and if the Metabolic Syndrome presents confounding issues for this treatment approach in Aging Frailty patients. This sub-study primarily focuses ...
Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
Technologybased inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...
Technologybased inGaithersburg, MASSACHUSETTS (USA)
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly ...
The current standard of care for autoimmune diseases is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and maligancies. Our approach to autoimmune disease is designed to ...
Technologybased inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
Technologybased inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
Technologybased inEindhoven, NETHERLANDS
Xeltis is a clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy. RestoreX™, Xeltis technology platform, is the world’s first polymer-based technology designed to enable natural restoration of ...
Fully synthetic restorative pulmonary heart valve for Right Ventricular Outflow Tract reconstruction, overtime turning into a living heart valve made of patient’s own ...
Technologybased inTaipei, City, TAIWAN
Bened Biomedical Co., Ltd. was founded in 2015 in Taipei, Taiwan. One of its founders, Professor Ying-Chieh Tsai (National Yang-Ming University), has spent decades studying fermentation and probiotics. It was in his lab where Bened’s first ...
Technologybased inSalt Lake City,, UTAH (USA)
Alucent Biomedical is a privately held biomedical company focused on our vision to transform the way vascular disease is treated. We are focused on using advanced technology to harness the body’s own natural physiologic processes and structures. ...
The Alucent NVS Vessel Restoration System is designed to create a natural, stent-like scaffold using the body’s own tissue and processes. An all-in-one, integrated procedural system, Alucent NVS combines standard angioplasty techniques with a ...
Technologybased inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater ...